Wright Investors Service Inc. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 43,246 shares of the biopharmaceutical company’s stock after selling 2,306 shares during the quarter. Gilead Sciences comprises about 1.0% of Wright Investors Service Inc.’s portfolio, making the stock its 29th biggest holding. Wright Investors Service Inc.’s holdings in Gilead Sciences were worth $3,098,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in GILD. Welch Investments LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the third quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in shares of Gilead Sciences during the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management increased its position in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.62 during trading hours on Wednesday, hitting $81.10. The stock had a trading volume of 6,517,606 shares, compared to its average volume of 8,940,619. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The stock has a market cap of $106,240.00, a price-to-earnings ratio of 10.55, a price-to-earnings-growth ratio of -1.86 and a beta of 1.24.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the prior year, the business posted $2.70 EPS. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year. research analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.81%. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is 27.05%.
In related news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total value of $1,108,050.00. Following the completion of the transaction, the executive vice president now owns 64,613 shares of the company’s stock, valued at approximately $4,772,962.31. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 50,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold a total of 430,268 shares of company stock valued at $34,074,395 in the last three months. Insiders own 1.30% of the company’s stock.
GILD has been the subject of a number of recent research reports. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research report on Wednesday, January 17th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Maxim Group set a $94.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Monday, December 11th. Finally, Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $79.02 to $96.00 in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $88.61.
WARNING: This news story was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/14/wright-investors-service-inc-has-3-10-million-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.